NERATINIB (HKI-272), AN IRREVERSIBLE PAN ERBB RECEPTOR TYROSINE KINASE INHIBITOR: PHASE 2 RESULTS IN PATIENTS WITH ERBB2+ADVANCED BREAST CANCER

被引：0
|
作者：
Paridaens, R. [1 ]
Badwe, R. [2 ]
Sun, Y. [3 ]
Dirix, L. [4 ]
Cardoso, F. [5 ]
Powell, C. [6 ]
Zacharchuk, C. [7 ]
Burstein, H. J. [8 ]
机构：
[1] Univ Hosp Gasthuisberg Katholieke, Leuven, Belgium
[2] Tata Mem Hosp, Dept Surg Oncol, Mumbai 400012, Maharashtra, India
[3] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[4] AZ St Augustinus, Oncol, Antwerp, Belgium
[5] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium
[6] Wyeth Ayerst Res, Biostat, Cambridge, MA USA
[7] Wyeth Ayerst Res, Oncol, Cambridge, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [41] Lapatinib, a dual ErbB-1/ErbB-2 kinase inhibitor, in the treatment of HER2-overexpressing locally advanced and metastatic breast cancer
    不详
    CLINICAL BREAST CANCER, 2006, 7 (03) : 224 - 227
  • [42] A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
    Rixe, Olivier
    Franco, Sandra X.
    Yardley, Denise A.
    Johnston, Stephen R.
    Martin, Miguel
    Arun, Banu K.
    Letrent, Stephen P.
    Rugo, Hope S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1139 - 1148
  • [43] A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
    Olivier Rixe
    Sandra X. Franco
    Denise A. Yardley
    Stephen R. Johnston
    Miguel Martin
    Banu K. Arun
    Stephen P. Letrent
    Hope S. Rugo
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1139 - 1148
  • [44] Safety and Efficacy of Neratinib in Combination with Capecitabine in Patients with ErbB2-Positive Breast Cancer
    Saura, C.
    Garcia-Saenz, J. A.
    Xu, B.
    Harb, W.
    Moroose, R.
    Pluard, T.
    Kiger, C.
    Germa, C.
    Wang, K.
    Kim, S-B
    CANCER RESEARCH, 2011, 71
  • [45] A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+Locally Advanced or Metastatic Breast Cancer
    Martin, M.
    Bonneterre, J.
    Geyer, C. E., Jr.
    Ito, Y.
    Ro, J.
    Lang, I.
    Kim, S-B
    Germa, C.
    Vermette, J.
    Van, M. L. Vo
    Wang, K.
    Wang, K.
    Awada, A.
    CANCER RESEARCH, 2011, 71
  • [46] Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
    Gonzales, Andrea J.
    Hook, Kenneth E.
    Althaus, Irene W.
    Ellis, Paul A.
    Trachet, Erin
    Delaney, Amy M.
    Harvey, Patricia J.
    Ellis, Teresa A.
    Amato, Danielle M.
    Nelson, James M.
    Fry, David W.
    Zhu, Tong
    Loi, Cho-Ming
    Fakhoury, Stephen A.
    Schlosser, Kevin M.
    Sexton, Karen E.
    Winters, R. Thomas
    Reed, Jessica E.
    Bridges, Alex J.
    Lettiere, Daniel J.
    Baker, Deborah A.
    Yang, Jianxin
    Lee, Helen T.
    Tecle, Haile
    Vincent, Patrick W.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) : 1880 - 1889
  • [47] The pan-ErbB inhibitor dacomitinib but not the dual EGFR/ErbB2 inhibitor labatinib disrupts membrane localization of the EGFR family of receptor tyrosine kinases
    Jathak, Maitreyee K.
    Steele, Thomas M.
    Siddiqui, Salma
    Mooso, Benjamin A.
    D'Abronzo, Leandro S.
    Drake, Christiana M.
    Ghosh, Paramita M.
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Characterization of human breast cancer cells with acquired resistance to the EGFR/ErbB-2 tyrosine kinase inhibitor lapatinib
    De Luca, Antonella
    Faraso, Stefania
    D'Alessio, Amelia
    Gallo, Marianna
    Lamura, Luana
    Maiello, Monica R.
    Normanno, Nicola
    CANCER RESEARCH, 2011, 71
  • [49] Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    Shimamura, Takeshi
    Ji, Hongbin
    Minami, Yuko
    Thomas, Roman K.
    Lowell, April M.
    Shah, Kinjal
    Greulich, Heidi
    Glatt, Karen A.
    Meyerson, Matthew
    Shapiro, Geoffrey I.
    Wong, Kwok-Kin
    CANCER RESEARCH, 2006, 66 (13) : 6487 - 6491
  • [50] Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer
    Goel, Peeyush N.
    Zhang, Hongtao
    Murali, Ramachandran
    Zheng, Cai
    Ji, Mei Q.
    Patterson, Angelica
    Grover, Payal
    Greene, Mark
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 651 : 39 - 46
12345